ESR1 and triple-negative breast carcinoma: However, the weak positivity of HER2, ER and PR or triple-negative breast cancer (HER2-/ER-/and PR-) requires additional examination with costly and higher technical assays, such as fluorescence in situ hybridization assay [11], [12], [13].